Etoposide phosphate - Generic Drug Details

What are the generic drug sources for etoposide phosphate and what is the scope of freedom to operate?

Etoposide phosphate is the generic ingredient in one branded drug marketed by Bristol Myers Squibb and Cheplapharm, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for etoposide phosphate. One supplier is listed for this compound.

Summary for etoposide phosphate

US Patents:	0
Tradenames:	1
Applicants:	2
NDAs:	2
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	105
What excipients (inactive ingredients) are in etoposide phosphate?	etoposide phosphate excipients list
DailyMed Link:	etoposide phosphate at DailyMed

Recent Clinical Trials for etoposide phosphate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
C17 Council	EARLY_PHASE1
Université de Sherbrooke	PHASE2
National Cancer Institute (NCI)	PHASE2

See all etoposide phosphate clinical trials

Pharmacology for etoposide phosphate

Drug Class	Topoisomerase Inhibitor
Mechanism of Action	Topoisomerase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for etoposide phosphate

L01CB	Podophyllotoxin derivatives
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for etoposide phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998		DISCN	No	No
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-001	Feb 27, 1998		DISCN	No	No
Cheplapharm	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020457-001	May 17, 1996		RX	Yes	Yes

Expired US Patents for etoposide phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998
Cheplapharm	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020457-001	May 17, 1996
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998
Cheplapharm	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020457-001	May 17, 1996
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-001	Feb 27, 1998
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-001	Feb 27, 1998

Etoposide phosphate Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Etoposide Phosphate?

Etoposide phosphate is a water-soluble prodrug of etoposide, primarily used as an anticancer agent for conditions such as lung cancer, lymphoma, and testicular cancer. The product's market is evolving due to factors including patent expirations, new formulation developments, and emerging treatment protocols.

Market Size and Growth Trends

The global oncological therapeutics market, which encompasses etoposide phosphate, was valued at approximately $154 billion in 2022. Etoposide phosphate's niche within this market is driven by its utility in chemotherapy protocols. The compound's sales are projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% from 2023 to 2028, reaching an estimated market size of $1.8 billion by 2028 [1].

Key Geographies

North America accounts for roughly 45% of the global oncology drug sales, driven by high cancer prevalence rates and established healthcare infrastructure. Europe contributes approximately 25%, with steady growth in emerging markets such as China and India, where increasing cancer incidences and expanding healthcare access contribute to demand.

Competitive Landscape

Major pharmaceutical companies, including Pfizer, GlaxoSmithKline, and Eli Lilly, produce etoposide phosphate formulations. Generic manufacturers are entering markets post-patent expiry, intensifying price competition. The availability of biosimilars and generic options is expected to impact pricing and market share over the next five years.

Regulatory and Patent Outlook

Etoposide phosphate was originally patented in the 1980s. Patent protections have since expired in various jurisdictions, enabling generic production. The lack of patent exclusivity limits pricing power but sustains volume-based sales. Regulatory approvals granted by authorities such as the FDA and EMA facilitate market access.

Market Drivers and Challenges

Drivers include rising global cancer incidence, approvals of new combination therapies incorporating etoposide phosphate, and increasing adoption in developing countries. Challenges involve the availability of alternative agents, post-patent generic competition, and potential toxicity concerns associated with chemotherapeutic agents.

---

What Is the Financial Trajectory for Etoposide Phosphate?

Revenue Projections

Global sales of etoposide phosphate are estimated at approximately $500 million in 2023 [2]. Sales growth is impacted by increased generic penetration, with revenues expected to decline gradually by 2-4% annually after peak generic entry, unless new formulations or indications are developed.

Cost Structure and Margins

Manufacturing costs for etoposide phosphate are relatively stable, with bulk production costs estimated at around 10-15% of sales revenue. Gross margins typically range from 35% to 45% in branded markets. Generic producers operate with margins exceeding 50% due to lower R&D expenses.

R&D and Investment Trends

Investment in developing new formulations, such as liposomal or targeted delivery systems, is limited given the drug's age and patent status. Companies focus on biosimilar development and combination therapy clinical trials. R&D expenses for new indications can range between $50 million and $150 million, primarily aimed at clinical trial support and regulatory processes.

Expected Impact of Market Dynamics on Financials

Post-2025, revenue decline is projected due to patent expirations and generic competition. However, revenues could stabilize if companies introduce novel formulations or expand indications, especially in areas like multidrug regimens for resistant cancers.

---

Key Takeaways

• Etoposide phosphate operates within a mature, slowly growing global oncology market.
• The product faces significant generic competition, leading to declining revenues after patent expiry.
• Growth hinges on the development of new formulations or combination therapies.
• Cost efficiency and R&D investments are modest, limited by patent and regulatory constraints.
• Future profitability depends on innovation and expanding into emerging markets.

---

FAQs

1. What are the primary indications for etoposide phosphate?
It is used mainly for lung cancer, lymphoma, and testicular cancer.

2. How has patent expiry affected the market?
Patent expiry has increased generic competition, reducing prices and profit margins.

3. Are there new formulations in development?
Few new formulations are in advanced stages; efforts focus on biosimilars and combination therapies.

4. What is the outlook for market growth?
Global sales are expected to decline modestly after patent expiration, with potential stabilization through new uses.

5. Which regions are driving future demand?
Emerging markets like China and India are expected to see increased demand due to rising cancer rates and improving healthcare access.

---

References

[1] MarketsandMarkets, “Oncology Drugs Market,” 2022.
[2] IQVIA, “Pharmaceutical Market Data,” 2023.